Healthcare Industry News: schizophrenia
News Release - April 19, 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business OfficerIndustry Veteran Brings 20 Years of Experience, Proven Success in Biotechnology Business Development
WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that Christopher L. Burnley has been appointed chief business officer. Mr. Burnley brings 25 years of broad industry experience focused on business operations, finance, strategy development and corporate development. In his new role, he will be responsible for shaping EnVivo’s long-term corporate strategy and executing its business development plans.
“We are very pleased to welcome a leader of Chris’ caliber to the EnVivo management team,” said Kees Been, president and chief executive officer of EnVivo Pharmaceuticals. “This is a pivotal time for EnVivo as we continue to advance our pipeline and our lead program, EVP-6124. Key corporate milestones this year include the upcoming Phase 2b results of this lead program in Alzheimer’s disease and the Phase 3 clinical trial initiation in schizophrenia. Chris’ track record of leveraging clinical programs to forge productive and collaborative corporate partnerships will be invaluable as we analyze the strategic options for EVP-6124.”
Prior to joining EnVivo, Mr. Burnley was a founder and CEO of VetRx, a biotechnology startup to develop human biologics for use in companion animals. Before forming VetRx, Mr. Burnley served as executive vice president and chief business officer and then executive vice president and chief operating officer of Phenomix Corporation, where he was responsible for business strategy, corporate development and finance, and negotiated a number of research and development collaborations, including partnerships with Forest Laboratories and Genentech. He also was vice president, business and operations of genomics at Monsanto Company, where he structured and managed a network of research and development collaborations. Prior to joining Monsanto, Mr. Burnley worked at Boston Consulting Group, where he assisted corporate clients on a wide range of topics and opened the firm’s Dallas office. Mr. Burnley holds B.S. degrees from Southern Methodist University in economics and political science and an M.B.A. from Harvard Business School.
“There is a critical unmet need for patients and significant demand from the industry for new and innovative treatments to treat CNS diseases like Alzheimer’s disease and schizophrenia,” said Mr. Burnley. “I am excited to be joining EnVivo at such an important time in the company’s life cycle and to work with the team to translate our diverse multi-target, multi-program pipeline into novel treatments that could improve patient care and quality of life.”
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, Inc. and its subsidiaries (“EnVivo Pharmaceuticals” or “EnVivo”) are dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS). EnVivo Pharmaceuticals, Inc. is a biotech company located in Watertown, Mass. The company’s focus is on building an integrated company and it is working to convert its broad pipeline into a range of CNS therapies that leverage novel mechanisms of action by altering the progression of disease and providing improvement in cognitive and overall function. EnVivo’s lead product is an alpha-7 nicotinic acetylcholine receptor agonist that has successfully completed a Phase 2b clinical trial in schizophrenia and is currently in an ongoing Phase 2b clinical trial for the treatment of cognitive impairment in Alzheimer’s disease. EnVivo’s other clinical programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi), a Gamma Secretase Modulator program and several preclinical programs, including a potent and selective PDE10 inhibitor program. For more information about EnVivo, visit www.envivopharma.com.
Source: EnVivo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.